The Part D Enhanced Medication Therapy Management Model launched in 2017 with the intention of incentivizing prescription drug plans (PDPs) to investigate new strategies to optimize medication therapy management (MTM) programs and ultimately reduce Medicare costs. This five-year program, launched across five different Part D regions, is about to come to an end, raising questions such as: What are some of the lessons learned? How could expanding the scope of traditional MTM programs improve outcomes? Health care solutions company Tabula Rasa HealthCare partnered with Blue Cross and Blue Shield Northern Plains Alliance, a model participant, to improve its MTM program. Now, the company has published a series of papers in the American Journal of Managed Care (AJMC) demonstrating how identifying at-risk patients and optimizing medication regimens at the pharmacist level can impact health care costs and outcomes for Medicare beneficiaries. This research builds on previous work conducted by Tabula Rasa HealthCare. Earlier in the year, the company published a study in the Journal of Patient Safety connecting medication risk scores with risk of death.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.